R&D Projects


Immunological and molecular characterization of lung cancer patients for immunotherapy.

The main objective of this project is to develop a tool for immunological and molecular characterisation for non-small-cell lung cancer patients in order to find a molecular signature that allows the stratification of patients regarding immunotherapy. It aims to integrate clinical, molecular, and immunological data specific to the tumour and identify the long-term survivors with these treatments. It is currently impossible to predict long-term survivors in advance using any known parameters.


patients diagnosed with lung cancer participate in the project


The challenge is to find a marker that identifies cancer patients who would be long-term survivors when treated with immunotherapy.


To this end, a cohort of 150 patients diagnosed with stage IV non-small-cell lung cancer will be recruited to investigate their immune status and the relationship with immunotherapy survival, paying special attention to those patients considered to be long-term survivors (> 2 years survival in total).

To achieve the objectives

Expediente: RTC-2017-6502-1 2018-2021

In order to successfully achieve the project’s objectives, a consortium has been formed between Atrys, leader of the project, the Puerta de Hierro Majadahonda University Hospital (FIBPH), and the Technological Centre Leitat.

This project has been funded by the Ministry of Science, Innovation, and Universities within the CHALLENGES-COLLABORATION Sub-programme, 2017 Call. The project is co-funded by the European Union with the aim of promoting technological development, innovation, and quality research.

Financial backers

Related projects

Modelo predictivo – GBM

Modelo predictivo – GBM

Identificación de un modelo predictivo de opción terapéutica en tumores cerebrales

Read more